ATE202569T1 - Prodrug-oligonukleotide - Google Patents
Prodrug-oligonukleotideInfo
- Publication number
- ATE202569T1 ATE202569T1 AT95934409T AT95934409T ATE202569T1 AT E202569 T1 ATE202569 T1 AT E202569T1 AT 95934409 T AT95934409 T AT 95934409T AT 95934409 T AT95934409 T AT 95934409T AT E202569 T1 ATE202569 T1 AT E202569T1
- Authority
- AT
- Austria
- Prior art keywords
- prodrug
- phosphate
- derivatized
- nucleotide
- oligonucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30213294A | 1994-09-07 | 1994-09-07 | |
| PCT/US1995/011477 WO1996007392A2 (en) | 1994-09-07 | 1995-09-07 | Oligonucleotide prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE202569T1 true ATE202569T1 (de) | 2001-07-15 |
Family
ID=23166398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95934409T ATE202569T1 (de) | 1994-09-07 | 1995-09-07 | Prodrug-oligonukleotide |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0779893B1 (de) |
| JP (1) | JPH10505094A (de) |
| AT (1) | ATE202569T1 (de) |
| AU (1) | AU3675195A (de) |
| CA (1) | CA2199464A1 (de) |
| DE (1) | DE69521517T2 (de) |
| WO (1) | WO1996007392A2 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5849905A (en) * | 1994-11-23 | 1998-12-15 | Centre National De La Recherche Scientifique | Biologically active phosphotriester-type nucleosides and methods for preparing same |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| AU4156197A (en) * | 1996-08-21 | 1998-03-06 | Hybridon, Inc. | Oligonucleotide prodrugs |
| WO1998008858A1 (en) * | 1996-08-26 | 1998-03-05 | Hybridon, Inc. | Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages |
| US6489304B2 (en) * | 1997-05-01 | 2002-12-03 | Hybridon, Inc. | Hyperstructure-forming carriers |
| AU2003290597A1 (en) | 2002-11-05 | 2004-06-03 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
| AU2004274021B2 (en) | 2003-09-18 | 2009-08-13 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| US20100178272A1 (en) | 2006-08-08 | 2010-07-15 | Klinische Pharmakologie | Structure and use of 5'phosphate oligonucleotides |
| EP1935434A1 (de) * | 2006-12-19 | 2008-06-25 | Novosom AG | Konstruktion und Verwendung von transfektionsverstärkenden Elementen |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
| WO2010072831A1 (en) * | 2008-12-23 | 2010-07-01 | Girindus America, Inc | Sulfurizing reagents and their use for oligonucleotides synthesis |
| WO2011005761A1 (en) * | 2009-07-06 | 2011-01-13 | Ontorii, Inc | Novel nucleic acid prodrugs and methods use thereof |
| AU2015255202B2 (en) * | 2009-07-06 | 2017-07-27 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods of use thereof |
| EP2620428B1 (de) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetrische hilfsgruppe |
| EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
| MX347361B (es) | 2011-07-19 | 2017-04-12 | Wave Life Sciences Ltd | Metodos para la sintesis de acidos nucleicos funcionalizados. |
| WO2014012081A2 (en) | 2012-07-13 | 2014-01-16 | Ontorii, Inc. | Chiral control |
| CA2879023C (en) | 2012-07-13 | 2017-03-28 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| SG11201500243WA (en) | 2012-07-13 | 2015-04-29 | Shin Nippon Biomedical Lab Ltd | Chiral nucleic acid adjuvant |
| EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
| JP6065263B2 (ja) * | 2012-10-25 | 2017-01-25 | 学校法人神奈川大学 | プロドラッグ化合物、オリゴヌクレオチド型プロドラッグ化合物の合成用試薬、及びオリゴヌクレオチド型プロドラッグ化合物の製造方法 |
| WO2015108046A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤 |
| WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| EP4137572A1 (de) | 2014-01-16 | 2023-02-22 | Wave Life Sciences Ltd. | Chirales design |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4547569A (en) * | 1982-11-24 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Intercalating agents specifying nucleotides |
| US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| FR2705099B1 (fr) * | 1993-05-12 | 1995-08-04 | Centre Nat Rech Scient | Oligonucléotides phosphorothioates triesters et procédé de préparation. |
-
1995
- 1995-09-07 AU AU36751/95A patent/AU3675195A/en not_active Abandoned
- 1995-09-07 EP EP95934409A patent/EP0779893B1/de not_active Expired - Lifetime
- 1995-09-07 WO PCT/US1995/011477 patent/WO1996007392A2/en active IP Right Grant
- 1995-09-07 CA CA002199464A patent/CA2199464A1/en not_active Abandoned
- 1995-09-07 JP JP8509709A patent/JPH10505094A/ja not_active Withdrawn
- 1995-09-07 AT AT95934409T patent/ATE202569T1/de not_active IP Right Cessation
- 1995-09-07 DE DE69521517T patent/DE69521517T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69521517T2 (de) | 2002-04-18 |
| WO1996007392A3 (en) | 1996-05-17 |
| EP0779893A2 (de) | 1997-06-25 |
| EP0779893B1 (de) | 2001-06-27 |
| DE69521517D1 (de) | 2001-08-02 |
| WO1996007392A2 (en) | 1996-03-14 |
| CA2199464A1 (en) | 1996-03-14 |
| AU3675195A (en) | 1996-03-27 |
| JPH10505094A (ja) | 1998-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE202569T1 (de) | Prodrug-oligonukleotide | |
| CA2278715A1 (en) | Aminooxy-modified oligonucleotides | |
| PT775149E (pt) | Novos grupos de proteccao e a sua utilizacao num processo melhorado para a sintese de oligonucleotidos | |
| EP1602725A3 (de) | Enzymatische Nukleinsäure die Abasische Nukleotide enthaltet | |
| CA2221448A1 (en) | Antisense oligonucleotide modulation of raf gene expression | |
| TR199801581T2 (xx) | �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler. | |
| EP1097162A4 (de) | Oligonukleotide mit für bindungstaschen spezifischen chiralen phosphorothioat-internukleosidbindungen | |
| WO2002018407A3 (de) | Antisense oligonukleotide gegen vanilloid rezeptor 1 | |
| CA2266748A1 (en) | Three component chimeric antisense oligonucleotides | |
| WO1999009154A3 (en) | Novel hiv-specific synthetic oligonucleotides and methods of their use | |
| DE69433626D1 (de) | N-2 substituierte purine | |
| AU6589094A (en) | 7-deazapurine modified oligonucleotides | |
| AU5918396A (en) | Nucleic acid detection and amplification by chemical linkage of oligonucleotides | |
| EP1700915A3 (de) | Enzymatische DNS-Moleküle | |
| ATE213019T1 (de) | Chimäre oligomere mit einer rns- spaltungsaktivität | |
| EP1325927A3 (de) | Synthese von Oligonukleotiden | |
| EP1329520A3 (de) | Sonde zur Diagnose einer ansteckenden Krankheit verursacht durch Staphylococcus aureus | |
| PT1053313E (pt) | Oligonucleotidos ''antisense'' optimizados complementares de sequencias de dna metiltransferase | |
| FR2723950B1 (fr) | Fragments nucleotidiques capables de s'hybrider specifiquemennt a l'adnr ou arnr des rickettsia et leur utilisation comme sondes ou amorces. | |
| WO1995003406A3 (en) | Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens | |
| AU5974194A (en) | Oligonucleotides with rna cleavage activity | |
| Scott | R & D: BASF invests in process engineering | |
| AU7613500A (en) | Methods and kits for determining mutations, local conformational changes, and amounts of nucleic acids by selective reaction of the 2'-ribose position in hybridized oligonucleotides | |
| FR2735492B1 (fr) | Procede de transformation catalytique d'hydrocarbures en composes aromatiques, avec un catalyseur contenant des lanthanides et du silicium | |
| EP1502950A3 (de) | Verfahren zur Reinigung von chemisch-modifiziertem RNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |